About this trial
Add-Aspirin is a large randomised clinical trial, which is taking place in the Republic of Ireland, UK and India. It will recruit 11,000 patients in total.
The Add-Aspirin trial is for people who have had, or have started treatment for, early stage cancer (cancer which has not spread) of the breast, stomach, oesophagus (food pipe), colon, rectum or prostate. The aim is to find out whether taking aspirin daily for 5 years after treatment for an early stage cancer, stops or delays the cancer coming back. This study will compare groups of people who take aspirin and those who take placebo tablets. Patients who are eligible to participate in this study will be randomily assigned (one chance in three) to one of three treatment groups via a process called randomization. Patients will receive either 300mg aspirin, 100mg aspirin or placebo everyday. The study is double-blind which means that neither the patients nor their study doctors will know which treatment they are receiving. Patients will be asked to take the tablets for 5 years in total as long as they do not have any serious side effects. Participants will be actively followed up for a further 10 years after treatment.
Patients who have undergone potentially curative treatment (surgery or other radical treatment) for early stage cancer of the breast, stomach, oesophagus (food pipe), colon, rectum or prostate.
Where’s this trial being run?
Beaumont Hospital, Bon Secours Cork, Cork University Hospital, Sligo University Hospital, St Luke’s Radiation Oncology Network @ St Luke’s Hospital, Tallaght University Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Galway, University Hospital Waterford, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
A phase III, double-blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
|Principal Investigator:||Prof Ray McDermott, Tallaght University Hospital and St Vincent's University Hosptial|
This is an academic sponsored study. University College London (UCL) and the Tata Memorial Centre (TMC) are co-sponsors of the trial.
Ireland: September 2018
|Global Recruitment Target:||11,000|
|Ireland Recruitment Target:||300|